In 2015, the Louisiana Legislature passed the Alison Neustrom Act, which paved the way for the production, recommendation, and use of therapeutic cannabis.
The LSU AgCenter is operating its Therapeutic Cannabis Program under one of the two licenses in Louisiana.
The LSU AgCenter selected GB Sciences Louisiana, LLC., as partner to cultivate and produce therapeutic cannabis products for patients with specific conditions. GB Sciences is a cannabis company focused on biopharmaceutical development, and has filed patent applications for use of cannabis therapies with neurodegenerative disease, chronic pain and heart therapies, as well as arthritis, Crohn’s disease, inflammatory bowel disease and asthma.
In compliance with the Act, approved medical care providers will oversee patients with debilitating conditions. Patients who have exhausted other medical options without a positive result may be recommended therapeutic cannabis by their practitioner, through specific delivery methods and specified dosages. The Louisiana State Board of Medical Examiners has developed stringent guidelines for doctors to recommend therapeutic cannabis, including regular follow-ups and reporting.
The LSU AgCenter continues to work closely with state regulators, including the Louisiana Department of Agriculture and Forestry, the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners to ensure that patient and public safety are at the forefront.
GB Sciences Louisiana began renovation of their production facility in April 2018 and anticipate product availability for patients by the fall of 2018. The production facility will not be located on LSU’s campus and no one under 21 years old will be employed in the facility.
Under the terms of the agreement, the LSU AgCenter will receive $3.4 million or 10 percent of gross revenue, whichever is greater, over five years. GB Sciences Louisiana will support LSU AgCenter research through funding for personnel, laboratory research space and equipment and an additional monetary contribution for research initiatives.
As the licensee, the LSU AgCenter is authorized to conduct research on therapeutic cannabis. The LSU AgCenter has had preliminary discussions with Pennington Biomedical Research Center and the Health Science Centers in New Orleans and Shreveport on opportunities for research collaboration.
As a public institution of higher education, the LSU AgCenter’s partnership with GB Sciences Louisiana represents a first in the therapeutic cannabis industry.
No taxpayer dollars will be spent on the project.
The LSU AgCenter and GB Sciences Louisiana anticipate production facility construction and renovations to be completed in the third quarter of 2018, and anticipate product availability by early fall. All products must be available through pharmacies licensed by the Louisiana Board of Pharmacy.
Qualifying Conditions (expanded May 2018)
Allowable Delivery Methods
Patients with qualifying medical conditions should discuss medical opportunities with their physicians.
The Louisiana State Board of Medical Examiners has developed rules relative to the recommendation of therapeutic cannabis by licensed physicians. Regulations include mandatory testing and qualifying by physicians and regular reporting of patient status. Additional information on the Board of Medical Examiners can be found at www.lsbme.la.gov .
The Louisiana State Board of Medical Examiners requires physicians complete an online registration course. CLICK HERE for the online Board Orientation and Courses.
For information on the Physician requirements and instructions for application, view attached .pdf.: LSBME PACKETpdf
Louisiana law limits the number of pharmacies to dispense therapeutic cannabis to ten licenses. These pharmacies have been selected by the Louisiana Board of Pharmacy through an application process. Additional information can be found at www.pharmacy.la.gov .
Regulations and Enforcement
The Louisiana Department of Agriculture and Forestry is named as the regulatory agency for the licensees. Information on the regulations can be found at www.ldaf.state.la.us, or click here for the current rules.
In this article:
|LSBME Instruction Packet|
|The Louisiana Law for Therapeutic Use of Marijuana|
|Will there be a research and development component added to the initiative?|
LSU AgCenter selected a vendor for medical marijuana
(06/15/17) BATON ROUGE, La. — The LSU AgCenter has notified the
Board of Supervisors of their intent to contract with GB Sciences, Inc., to
produce a medical marijuana product for qualifying patients. GB Sciences will
work under the LSU AgCenter license in compliance with state law and rules
established by regulatory agencies.
Agriculture and Medicine
While Louisiana has had legislation since the late 1970s regarding medical
marijuana, the lack of enabling rules and regulations prevented patient access
until the passage of Senate Bill 143 in 2015. Sen. Fred Mills, of Breaux
Bridge, authored the legislation, paving the way for the production,
recommendation and use of medical marijuana. The act (La R.S. 40:1046) became
known as the Alison Neustrom Act, in honor of Dr. Alison Neustrom, of
Lafayette, who was an advocate for medical marijuana. At 42, Dr. Neustrom
passed away from aggressive pancreatic cancer.
LSU AgCenter opts in to medical marijuana production initiative
(06/24/16) BATON ROUGE, La. – The LSU Board of Supervisors on Friday (June 24)
approved a resolution allowing the LSU AgCenter to begin taking steps needed to
obtain a license to produce medical marijuana as part of a state initiative.
PART X-E. THERAPEUTIC USE OF MARIJUANA
§1046. Prescription of marijuana for therapeutic use; rules and regulations; Louisiana Board of Pharmacy and the adoption of rules and regulations relating to the dispensing of prescribed marijuana for therapeutic use; the Department of Agriculture and Forestry and the licensure of a production facility.
For the full law go to this link: http://www.legis.la.gov/Legis/Law.aspx?d=96986
The potential for research in both the plant strain development arena and in extraction, formulation and compounding of the drug are important elements in the initiative. The law, as signed by the governor, addressed research separate and apart from production. Future success of the initiative will depend in part on our ability to produce superior plants using our biotechnology techniques to develop strains for expression of specific compounds in the plant. Equally important will be the opportunity for basic clinical research conducted by the Pennington Biomedical Research Center and the LSU Health Sciences Center to formulate and compound the drug compounds to certain disease states as outlined in the law. Research and data collection also ensure that science is directing the future of the program.